安旭生物2025年业绩预减，募投项目延期至2027年

Core Viewpoint - Anxu Bio (688075) has disclosed its 2025 performance forecast, expecting a significant decline in net profit and a delay in its fundraising project until 2027 [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan, representing a year-on-year decrease of 55.80% to 63.08% [2] - The expected non-recurring net profit is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decline of 58.84% to 65.70% [2] - The performance decline is primarily attributed to increased tariffs in the U.S. leading to reduced orders, foreign exchange losses due to currency fluctuations, decreased interest income, and asset depreciation [2] Project Progress - The company announced on January 30, 2026, that the completion date for its "in vitro diagnostic reagents and diagnostic instruments R&D and production project" has been postponed from January 2026 to January 2027 [3] - The delay is attributed to the impact of global respiratory infectious diseases on renovation progress and delays in equipment investment [3] Company Status - Shareholder Ma Huaxiang reduced his stake in the company by selling 804,500 shares between January 6 and January 21, 2026, decreasing his holding from 11.62% to 10.99%, which has reached the 1% threshold for equity change [4] Business and Technical Development - The company is actively transitioning from a single product focus to a comprehensive health management approach, including the expansion of pet testing products and chronic disease management apps [5] - The company is deepening its overseas market presence, with multiple international certifications expected in 2025, although related investments may lead to increased short-term expenses [5]